A biological explanation for our finding may be forthcoming because there is a growing trend towards expanding genetic testing in women with strong family histories and early-onset breast cancer who are not BRCA1/2 mutation carriers to identify other germline breast cancer susceptibility mutations, such as p53, PTEN, PALB2, and CDH1 [38–40]. The gene discussed is TP53; the disease is breast carcinoma.